Aditxt Submits Emergency Use Authorization (EUA) Application for AditxtScore™ for COVID-19
August 24 2020 - 8:30AM
via NEWMEDIAWIRE ‒ Aditx Therapeutics, Inc. (Aditxt) (the
“Company”) (Nasdaq: ADTX), a life sciences company developing
biotechnologies focused on improving the health of the immune
system through immune monitoring and reprogramming, today announced
that it has submitted an Emergency Use Authorization (EUA)
application with the U.S. Food and Drug Administration (FDA) for
AditxtScore™ for COVID-19, for use in detecting antibodies against
SARS-CoV-2 antigens.
Amro
Albanna, Co-founder and Chief Executive Officer of Aditxt, stated,
“The submission of an EUA to the FDA is one of the key steps to
making AditxtScore for COVID-19, and AditxtScore platform as a
whole, commercially available. The granting of an EUA by the
FDA, would allow us to distribute AditxtScore for COVID-19
throughout the country. We look forward to contributing to the
solution to the COVID-19 global pandemic.”
About
Aditx Therapeutics
Aditxt
is developing technologies specifically focused on improving the
health of the immune system through immune monitoring and
reprogramming. The immune monitoring technology is designed to
provide a personalized comprehensive profile of the immune system.
The immune reprogramming technology is currently at the
pre-clinical stage and is designed to retrain the immune system to
induce tolerance with an objective of addressing rejection of
transplanted organs, autoimmune diseases, and allergies. For more
information, please visit www.aditxt.com.
Forward-Looking Statements
Certain
statements in this press release constitute “forward-looking
statements” within the meaning of the federal securities laws.
Forward-looking statements include statements regarding the
Company’s intentions, beliefs, projections, outlook, analyses or
current expectations concerning, among other things, the Company’s
ongoing and planned product development; the Company’s intellectual
property position; the Company’s ability to develop commercial
functions; expectations regarding product launch and revenue; the
Company’s results of operations, cash needs, spending, financial
condition, liquidity, prospects, growth and strategies; the
industry in which the Company operates; and the trends that may
affect the industry or the Company. Forward-looking statements are
not guarantees of future performance and actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, as well as those risks
more fully discussed in the section entitled “Risk Factors” in the
Company’s prospectus, dated June 29, 2020, that was filed with the
U.S. Securities and Exchange Commission under File No. 333-235933,
as well as discussions of potential risks, uncertainties, and other
important factors in the Company’s subsequent filings with the U.S.
Securities and Exchange Commission. All such statements speak only
as of the date made, and the Company undertakes no obligation to
update or revise publicly any forward-looking statements, whether
as a result of new information, future events or otherwise.
Investor Relations Contact:PCG AdvisoryJeff RamsonChief
Executive Officer646-762-4518IR@aditxt.com www.aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Apr 2023 to Apr 2024